CIBERNED - Centro de Investigación Biomédica en Red

What CIBERNED - Centro de Investigación Biomédica en Red does

CIBERNED (Centro de Investigación Biomédica en Red - Enfermedades Neurodegenerativas) is one of 13 thematic research areas within the CIBER consortium, a publicly funded biomedical research network created in 2006 under Spain's Instituto de Salud Carlos III (ISCIII) and the Ministry of Science and Innovation. It coordinates research on neurodegenerative diseases spanning Alzheimer's disease and other dementias, Parkinson's, Huntington's, ALS and other neuromuscular disorders, and neuroinflammation, drawing on 508 research groups across 106 Spanish institutions and over 7,400 affiliated professionals. The consortium is administered by a small core staff of 34 based in Madrid and operates under a 2024-2026 Strategic Plan.

Its core research infrastructure includes the IMPaCT strategic programs (Cohort, Genómica, Predictive Medicine), the SEED-ALS network (Spain's largest ALS research network with 600+ recruited patients and €3.9M ISCIII funding), and access to NANBIOSIS singular scientific-technical infrastructure for collaborative biomedical solution development. Technology transfer activities are channeled through a dedicated platform with a track record of 182 European patent applications between 2001 and 2020, ranking CIBERNED among the top 3 Spanish public research organizations for patent filings. Citizen engagement is formalized through a 2025-2026 Citizen Participation Action Plan.

CIBERNED does not operate commercial pricing or a traditional go-to-market motion. Revenue is derived from public research funding (ISCIII core allocations and Ministry of Science and Innovation oversight), competitive research grants (including inter-area project calls and ACCI cooperative actions), technology transfer and patent licensing, and public-private collaboration such as the AbbVie partnership for Parkinson's care model optimization. End users include the Spanish public health system, research communities, patient associations, and individual patients participating in cohort and clinical studies.

Name

CIBERNED - Centro de Investigación Biomédica en Red

Legal name

CIBERNED - Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas

Website

https://ciberned.es

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

CIBERNED is a publicly funded Spanish biomedical research consortium under ISCIII coordinating 508 research groups across 106 institutions to study Alzheimer's, Parkinson's, ALS, and other neurodegenerative diseases, delivering collaborative research programs, precision medicine infrastructure, and technology transfer for the Spanish public health system.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Colleges, Universities, and Professional Schools (6113)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Membership Organizations (8600), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Neurodegenerative disease research
• Biomedical research consortium
• Precision medicine studies
• Clinical research networks
• Technology transfer services

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Others

Revenue model

1. Public Research Funding: Core funding from Instituto de Salud Carlos III (ISCIII) and Ministry of Science and Innovation, providing the primary financial foundation for consortium operations and research programs.
2. Competitive Research Grants: Project funding through competitive calls including inter-area projects, ACCI (Acciones Cooperativas y Complementarias Intramurales), and international collaborative grants supporting specific research initiatives.
3. Technology Transfer and Patenting: Innovation revenue through patent filings and Technological Development Platform collaborations with private companies, with the consortium ranking among top 3 Spanish public research organizations for European patent applications (182 requests 2001-2020).
4. Public-Private Collaboration: Strategic partnerships with pharmaceutical and biotech companies for joint research projects, clinical development, and technology development as demonstrated by the AbbVie collaboration on Parkinson's care optimization.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

CIBERNED is a publicly-funded Spanish biomedical research consortium that coordinates multi-institutional research on neurodegenerative diseases (Alzheimer's, Parkinson's, ALS, Huntington's, and neuroinflammation) across 508 research groups from 106 institutions. Its core offerings include collaborative research programs, the SEED-ALS national research network, IMPaCT precision medicine platforms (Genomics and Cohort), technology transfer services (Oferta Tecnológica), and training programs for young researchers. The consortium is funded by ISCIII and the Ministry of Science and Innovation, with no commercial pricing.

Product overview

CIBERNED is a biomedical research consortium (not a product company) focused on neurodegenerative diseases operating under the CIBER framework of the Instituto de Salud Carlos III. The organization functions as a collaborative research network comprising 508 research groups from 106 institutions with over 7,400 professionals. The main offerings include research programs on specific disease areas (Alzheimer's, Parkinson's, ALS, neuroinflammation), technology transfer services (Oferta Tecnológica), webinar series for researchers (CIBERNED Webinar Series), young researcher workshops, and scientific meetings. The consortium coordinates initiatives like the SEED-ALS project (funded by ISCIII with 3.9 million euros) for ALS research, and manages the DEGESCO resource for research support.

Differentiator

Problem solved

Functional benefit

Products and services

• Oferta Tecnológica (Technology Offer) Technology transfer service showcasing available technologies, capabilities and services developed by CIBERNED research groups for potential commercialization or collaboration with industry partners.
• CIBERNED Webinar Series Online seminar series providing scientific education and knowledge sharing among CIBERNED researchers and the broader scientific community on neurodegenerative disease topics.
• CIBERNED Workshops for Young Researchers (Personal Científico Joven) Workshop program designed to support and develop early-career researchers (Personal Científico Joven) within the CIBERNED consortium, supporting researcher development and career advancement.
• SEED-ALS Research Project A major research project funded by ISCIII (3.9 million euros) focused on Amyotrophic Lateral Sclerosis (ALS/ELA), having recruited over 600 patients to establish Spain's largest ALS research network for accelerating diagnosis and treatment development.

Quantifiable outcome

• 600+ patients recruited in SEED-ALS, establishing largest ALS research network in Spain
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and major.

• AbbViecoreStrategic or Co-development Partner · 25 June 2026Collaboration with AbbVie for developing a strategic health initiative to optimize care processes for advanced Parkinson's disease in Spain. The initiative involves a multidisciplinary expert committee designing an optimal, equitable care model with AbbVie providing pharmaceutical industry expertise and funding.
• Instituto de Salud Carlos III (ISCIII)coreStrategic or Co-development PartnerParent institution providing core funding and institutional framework for the consortium. Coordinates IMPaCT strategic programs (Cohort, Genomics, Predictive Medicine) and SEED-ALS project funding (3.9 million euros). ISCIII Director Marina Pollán Santamaría serves as President of CIBER's Governing Council.
• CIBER (Centro de Investigación Biomédica en Red)coreStrategic or Co-development PartnerParent consortium structure encompassing 13 thematic areas including CIBERNED, with unified strategic planning, shared services, and cross-area project funding mechanisms. CIBER comprises 508 research groups from 106 institutions.
• NANBIOSISmajorTechnology or IntegrationCollaborative use of NANBIOSIS singular scientific-technical infrastructures for developing biomedical solutions in cancer, rare diseases, and personalized medicine research projects.
• CIBERER (CIBER de Enfermedades Raras)majorStrategic or Co-development PartnerCollaborative partner area within CIBER consortium, with joint scientific initiatives including Neuro&Rare 2026 Joint Scientific Meeting combining neurodegeneration and rare disease research.
• IMPaCT Cohorte ProgrammajorTechnology or IntegrationISCIII strategic program for precision medicine cohort research, with CIBER coordination. New workstreams added in 2025 focusing on ocular health, environment, genomics, and electronic health record integration.
• IMPaCT Genómica ProgrammajorTechnology or IntegrationISCIII strategic program for genomic diagnostics, with CIBER coordination. Reached milestone of 2,000+ whole genome sequences for rare disease patients without diagnosis and suspected hereditary cancer cases.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• German Center for Neurodegenerative Diseases (DZNE): Germany's national public research consortium dedicated to neurodegenerative diseases, operating across 10 sites with a similar multi-institutional collaborative model - the closest functional analog to CIBERNED at larger scale.
• Institut des Maladies Neurodégénératives (IMN, formerly ENP): France's national neuroscience research center with multi-site structure and similar public-mission mandate for neurodegenerative diseases (Alzheimer's, Parkinson's, ALS, Huntington's), directly comparable to CIBERNED's disease portfolio.
• Karolinska Institutet - Neurodegeneration Research Group: Swedish academic medical center with leading European neurodegenerative disease research programs and clinical trial infrastructure, comparable as a university-affiliated research network with public funding.
• CIBERER (CIBER de Enfermedades Raras): Sister thematic area within the same CIBER consortium under ISCIII; shares CIBERNED's governance, funding mechanisms, and parent structure but focuses on rare diseases, with joint scientific initiatives like Neuro&Rare 2026.
• UK Dementia Research Institute (UKDRI): UK national center of excellence funded by UKRI and charity partners to drive research into dementia and neurodegenerative disease, sharing CIBERNED's consortium structure, public funding backbone, and translational focus.

Broad incumbents

• Mayo Clinic Alzheimer's Disease Research Center: NIH-funded AD Research Center within Mayo Clinic conducting integrated basic, translational, and clinical neurodegenerative research at significantly larger scale and budget than CIBERNED.

Emerging players

• Allen Institute for Brain Science: US-based nonprofit research organization producing large-scale open neuroscience datasets and tools with public-private funding model; comparable in mission-driven research structure though broader in scope than neurodegeneration alone.
• Alzheimer's Disease Cooperative Study (UC San Diego): NIH-funded consortium coordinating multi-site clinical trials for Alzheimer's treatments across US institutions, sharing CIBERNED's multi-center collaborative trial model.

Others

• Michael J. Fox Foundation for Parkinson's Research: Large US patient-driven foundation funding Parkinson's research globally with significant partnership programs; relevant as a counterpart funder/partner for CIBERNED's Parkinson's programs but operates via grant-making rather than in-house research.

Regional players

• Neurodegeneration Cluster Dresden: Regional German neurodegenerative research cluster (within DZNE) focusing on cellular mechanisms of neurodegeneration - though geographically distinct, it represents a comparable sub-national research concentration model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ciberned

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CIBERNED - Centro de Investigación Biomédica en Red